Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 GeneticVariation phenotype BEFREE Our method could be applied to 97% of FLT3-ITD-positive patients and was as sensitive as other MRD parameters such as PML-RARA , NPM1 mutations, or MLL -PTD (correlation: r = 0.63; 0.99, and 0.99, respectively). 22458420 2012
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 Biomarker phenotype BEFREE PML/RARa-based MRD monitoring by RQ-PCR may allow us to identify subgroups of patients at low risk of relapse after induction. 22407853 2012
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 Biomarker phenotype BEFREE Longitudinal RT-PCR of PML/RARalpha allows sensitive assessment of response to treatment and minimal residual disease (MRD) monitoring in APL. 17217043 2007
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 Biomarker phenotype BEFREE The detection of PML-RARalpha by real-time polymerase chain reaction (RQ-PCR) is becoming an important tool for monitoring minimal residual disease (MRD) in patients with acute promyelocytic leukemia (APL). 17339180 2007
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 AlteredExpression phenotype BEFREE The detection of the PML-RARA fusion gene by reverse-transcription polymerase chain reaction (RT-PCR) is routinely used for diagnosis and monitoring of minimal residual disease (MRD). 15179005 2004
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 GeneticVariation phenotype BEFREE A total of 98 samples, comprising four groups, were evaluated: Group 1, 16 diagnostic samples molecularly positive by our existing laboratory-developed assays for PML-RARalpha/t (15;17) or BCR-ABL/t (9;22); Group 2, 51 diagnostic samples negative by our laboratory-developed assays for PML-RARalpha/t (15;17) or BCR-ABL/t (9;22); Group 3, 21 prospectively analyzed diagnostic cases, without prior molecular studies; and Group 4, 10 minimal residual disease (MRD) samples. 14573782 2003
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 Biomarker phenotype BEFREE Recent studies suggest that rigorous MRD monitoring, coupled with pre-emptive therapy at the point of molecular relapse improves survival in the relatively small subgroup of PML-RARalpha positive patients with 'poor risk' disease. 12357347 2002
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 GeneticVariation phenotype BEFREE Acute promyelocytic leukaemia (APL) is characterized by the t(15;17)(q22;q21) leading to the formation of PML-RARalpha and RARalpha-PML fusion genes which provide suitable targets for the assessment of minimal residual disease (MRD). 11987921 2002
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 Biomarker phenotype BEFREE Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. 11681409 2001
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 AlteredExpression phenotype BEFREE Serial quantitation of MRD in both BM and PB samples showed significantly lower levels of PML-RARalpha transcripts in remission, although the majority of samples remain positive for the PML-RARalpha transcripts even those in long-term remission (up to 94 months). 11455974 2001
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 AlteredExpression phenotype BEFREE We studied retrospectively the clinical feasibility of minimal residual disease (MRD) monitoring by reverse transcription-polymerase chain reaction (RT-PCR) detecting the PML/retinoic acid receptor alpha (RARalpha) chimeric gene in children with acute promyelocytic leukemia (APL). 11318028 2001
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 AlteredExpression phenotype BEFREE Minimal residual disease (MRD) was prospectively monitored at the 10(-5) level by the reverse transcriptase-polymerase chain reaction (RT-PCR) of PML-retinoic acid receptor alpha (RARA) transcripts from 27 acute promyelocytic leukemia (APL) patients who achieved complete remission (CR) with all-trans retinoic acid and chemotherapy (previously untreated patients, 15; refractory to chemotherapy or relapsed, 12). 7723389 1995
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 Biomarker phenotype BEFREE Appropriate oligoprimers complementary to PML and RAR-a sequences nearby the DNA breakpoints may be successfully used in PCR experiments to amplify the PML/RAR-a hybrid gene and sensitively detect minimal residual disease. 8180596 1994
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 GeneticVariation phenotype BEFREE The RT/PCR procedure has been established to characterize the expression patterns of the PML-RARA fusion gene and to detect minimal residual disease (MRD). 1337847 1992
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 GeneticVariation phenotype BEFREE The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reaction. 1310060 1992
Entrez Id: 5371
Gene Symbol: PML
PML
0.100 Biomarker phenotype BEFREE The consistent identification by RT-PCR of the fusion of the PML and RAR alpha genes in AML3 patients suggest that this method will provide a useful tool for the diagnosis and detection of minimal residual disease in these patients. 1375840 1992